{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:44:06Z","timestamp":1791477846585,"version":"4.3.4"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent guidelines for SLE recommend using a hydroxychloroquine (HCQ) dose less than 5.0\u2009mg\/kg\/day to reduce the risk of retinopathy. To determine if this dose reduction would have an impact on the clinical course of SLE, we compared flare incidence in a cohort of patients with SLE treated with two different oral HCQ dosages (\u22645\u2009mg\/kg\/day or &gt;5\u2009mg\/kg\/day). As a secondary analysis, we compared HCQ blood levels between the two different oral dosages, and evaluated the frequency of non-adherence in patients with SLE treated with HCQ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified a cohort of patients with SLE taking HCQ for at least 6 months and followed for 24 months. At study entry and 6 months later, a blood venous sample was taken to measure HCQ blood levels by liquid chromatography. Incidence of new SLE flares after recruitment was put in relation to daily HCQ dose and mean HCQ blood levels. Cox regression analysis served to identify factors associated with SLE flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>83 patients were enrolled. We observed 11 (16%) flares that developed in mean 14.8 months of follow-up. The difference in terms of flare rate and mean HCQ blood levels between the two oral dosages was not statistically significant. There was a trend (p=0.08) for high HCQ dose being associated with a lower flare rate. At Cox analysis, higher HCQ blood levels and older age at baseline were protective against flare occurrence, while concomitant immunosuppressant therapy showed significant positive association. HCQ blood levels did not correlate with prescribed HCQ dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with low oral HCQ dosage tend to have more flares, although the difference was not statistically significant. Higher HCQ blood levels were protective against flare occurrence. The risks and benefits must be balanced in choosing HCQ dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2022-000841","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:51:53Z","timestamp":1673434313000},"page":"e000841","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-4551","authenticated-orcid":false,"given":"Serena","family":"Fasano","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Precision Medicine, University of Campania, \"Luigi Vanvitelli\", Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Messiniti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision Medicine, University of Campania, \"Luigi Vanvitelli\", Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iudici","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania Alessia","family":"Coscia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision Medicine, University of Campania, \"Luigi Vanvitelli\", Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision Medicine, University of Campania, \"Luigi Vanvitelli\", Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2025091513302842000_10.1.e000841.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297"},{"key":"2025091513302842000_10.1.e000841.2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(07)60591-1","article-title":"Hydroxychloroquine in systemic lupus erythematosus","volume":"369","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Lancet"},{"key":"2025091513302842000_10.1.e000841.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"key":"2025091513302842000_10.1.e000841.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303"},{"key":"2025091513302842000_10.1.e000841.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161351"},{"key":"2025091513302842000_10.1.e000841.6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091513302842000_10.1.e000841.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090994"},{"key":"2025091513302842000_10.1.e000841.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu451"},{"key":"2025091513302842000_10.1.e000841.9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90345-E"},{"key":"2025091513302842000_10.1.e000841.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"2025091513302842000_10.1.e000841.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"2025091513302842000_10.1.e000841.12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/art.41683","article-title":"ACR, AAD, RDS, and AAO 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity","volume":"73","author":"Rosenbaum","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091513302842000_10.1.e000841.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091513302842000_10.1.e000841.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215573"},{"key":"2025091513302842000_10.1.e000841.15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/acr.24155","article-title":"Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"73","author":"Garg","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025091513302842000_10.1.e000841.16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cpt.885","article-title":"A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires","volume":"103","author":"Costedoat-Chalumeau","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025091513302842000_10.1.e000841.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2025091513302842000_10.1.e000841.18","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538"},{"key":"2025091513302842000_10.1.e000841.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025091513302842000_10.1.e000841.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2025091513302842000_10.1.e000841.21","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025091513302842000_10.1.e000841.22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0961203317717631","article-title":"Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease","volume":"27","author":"Iudici","year":"2018","journal-title":"Lupus"},{"key":"2025091513302842000_10.1.e000841.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150379"},{"key":"2025091513302842000_10.1.e000841.24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025091513302842000_10.1.e000841.25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"2025091513302842000_10.1.e000841.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221295"},{"key":"2025091513302842000_10.1.e000841.27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-020-02282-0","article-title":"Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study","volume":"22","author":"Fernandez-Ruiz","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025091513302842000_10.1.e000841.28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000395"},{"key":"2025091513302842000_10.1.e000841.29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091513302842000_10.1.e000841.30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0961203317728810","article-title":"Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic latin American cohort","volume":"27","author":"Ugarte-Gil","year":"2018","journal-title":"Lupus"},{"key":"2025091513302842000_10.1.e000841.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket322"},{"key":"2025091513302842000_10.1.e000841.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241002"},{"key":"2025091513302842000_10.1.e000841.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330105"},{"key":"2025091513302842000_10.1.e000841.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111061"},{"key":"2025091513302842000_10.1.e000841.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067835"},{"key":"2025091513302842000_10.1.e000841.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.22156"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2022-000841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:30:32Z","timestamp":1757968232000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2022-000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/lupus-2022-000841"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2022-000841","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}